Invex Therapeutics Ltd - IXC share price

About

Invex Therapeutics Ltd is an Australia-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialisation of Presendin (Exenatide) for neurological conditions relating to raised intracranial pressure. The Company received written responses from the United States Food and Drug Administration (FDA) Division of Neurology relating to its proposed Phase III clinical trial design for Presendin in Idiopathic Intracranial Hypertension (IIH). Exenatide is a glucagon-like peptide-1 receptor agonist approved for the treatment of type II diabetes. The Company focuses on reformulating Exenatide to deliver it in a way that enables exploitation of its unknown ability to reduce cerebral spinal fluid secretion in the choroid plexus of the brain. The Company intends to progress expediently to clinical evaluation and undertake the registration of different formulations of Exenatide optimized to treat different neurological conditions.